vaccine delivery News
-
Micron Biomedical Presents at the White House Summit on the Future of COVID-19 Vaccines
Dr. Mark Prausnitz, co-founder and Chief Scientific Advisor of Micron Biomedical (“Micron”), today presented Micron’s technology for the simple administration of vaccines and therapeutics at a White House panel discussion titled Innovation in Vaccine Delivery chaired by Dr. Francis Collins. This summit outlined a path toward innovative, next-generation COVID-19 vaccines and ...
-
OncoImmunity starts a personalized cancer vaccine project with a Chinese biotech company
OncoImmunity teams up with an innovative China based high-tech biotechnology company that has developed a dendritic cell-based vaccine delivery platform. The Chinese vaccine company is developing a personalized cancer vaccine solution with its platform that promises to deliver potent anti-tumor immune responses in vaccinated patients. The collaboration will demonstrate the power of the ...
-
AKCP Develops COVID-19 Vaccine Delivery Monitoring
AKCP Coronavirus Vaccine Delivery Monitoring Solution The COVID-19 vaccines coming from Pfizer and Moderna both require storage and transportation at low temperatures. The Pfizer vaccine at -70°C +/- 10°C whereas Moderna requires -20°C. Both can be transferred to standard medical refrigerators for short periods of time. The latest COVID-19 vaccine to be announced from AstraZeneca ...
By AKCP
-
Aerogen leading the way for inhaled COVID-19 vaccine delivery
Company’s aerosol drug delivery technology used in Phase 1 clinical trial to deliver inhaled type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults without COVID-19 from China The Aerogen Solo is a closed-system, single-patient-use aerosol drug delivery technology1 that mitigates the transmission of patient-generated infectious aerosol during ventilation2–7. Hospitals around the ...
By Aerogen
-
Vaxxas and University of Sydney complete study assessing needle-free HD-MAP technology for vaccine administration
Australian biotechnology company, Vaxxas Pty Ltd (Vaxxas), in collaboration with the University of Sydney Institute for Infectious Diseases, Faculty of Medicine and Health, has completed a study assessing the usability and acceptability of its novel High-Density Microarray Patch (HD-MAP) to administer vaccines. The HD-MAP is Vaxxas’ proprietary vaccine patch technology, representing a ...
By Vaxxas, Inc.
-
New Publication On Abera’s Vaccine Platform in the Journal Microbial Cell Factories
Abera Bioscience AB (“Abera” or “the Company”) continues to improve its vaccine platform in collaboration with researchers at Vrije Universiteit Amsterdam. An article was recently published in the peer-reviewed journal Microbial Cell Factories by researchers Trang H. Phan, Coen Kuijl and Peter van Ulsen of Vrije Universiteit Amsterdam in collaboration with Abera’s ...
-
Aerogen and CanSinoBIO agree on landmark development and commercial supply partnership for world’s first inhaled Covid-19 vaccine delivery
Following months of collaborative development work, Aerogen® (Galway, Ireland) and CanSinoBIO (SSE: 688185, HKEX: 06185) (Tianjin, China) have announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIO’s Recombinant Novel Coronavirus Vaccine Convidecia™ utilizing Aerogen’s proprietary vibrating mesh aerosol drug delivery technology. The ...
By Aerogen
-
POP BIO awarded $599,981 Phase 1 SBIR Award to Develop Thermostable COVID-19 Vaccine
BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $599,981, two-year Phase I Small Business Innovation Research (SBIR) under Award No. 1R43AI165089-01, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to pursue development of a potentially life-saving vaccine technology to address the ongoing ...
-
Micron Biomedical Initiates First-Ever Microneedle Vaccine Clinical Trial in Children
– Phase 1/2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of Micron’s Microneedle-Based Measles-Rubella Vaccine – ATLANTA, July 13, 2021 /PRNewswire/ – Micron Biomedical, Inc. (“Micron” or the “Company”), a leader in dissolving, microneedle-based vaccine and drug delivery, today announced that it has initiated a Phase 1/2 clinical ...
-
Micron Biomedical Progresses with Clinical Evaluation of its Technology for Measles-Rubella Vaccination
Under $6.745 Million Grant from the Bill & Melinda Gates Foundation ATLANTA, Sept. 1, 2020 /PRNewswire/ — Micron Biomedical, Inc. (Micron) recently received a second tranche of funding ($2.6M) to continue clinical development of its microneedle-based technology for measles and rubella vaccination from the Bill & Melinda Gates Foundation. This work leverages Micron’s ...
-
Covid-19 Vaccine Developed By Ub Startup Enters Human Trials
A COVID-19 vaccine candidate developed by a UB spinoff company has progressed to human trials in South Korea, according to a UBNow story. The vaccine candidate, called EuCorVac-19, was jointly developed by Buffalo biotech company POP Biotechnologies and South Korean biotech company EuBiologics. POP Biotechnologies was founded in 2015 by former UB students Kevin Carter and Jonathan Smyth and UB ...
-
How to freeze-dry a potential COVID-19 vaccine
Things that are freeze-dried: Astronaut food. Emergency rations. And, just maybe, some future COVID-19 vaccines. Freeze-drying is a method for removing water from a product. First, you freeze the item you’re trying to dehydrate, causing any water in it to become ice. Then, you remove the ice through a process called sublimation, in which ice turns directly into vapor under low pressure. In ...
-
Steven Damon Appointed Chief Executive Officer of Micron Biomedical, A Novel Vaccine and Therapeutic Technology Company
ATLANTA, June 1, 2020 /PRNewswire/ — Micron Biomedical, Inc., an Atlanta based biopharmaceutical company, has appointed industry veteran, Steven Damon, as the company CEO. Mr. Damon will lead Micron on a path to rapid development and commercialization of Micron’s proprietary dissolvable, microneedle-based technology, a novel technology designed for simple, safe and effective ...
-
SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19
SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19 Oxford, UK, September 8: SpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases, today announces that its partner the Serum Institute of India (SIIPL) has dosed the first ...
-
Alfa Chemistry-A New Supplier of Vaccine Excipients, Nucleic Acid Delivery Excipients and SARS-CoV-2 Detection Raw Materials
Alfa Chemistry, known as a chemical supplier for various high-quality chemicals and materials for both academia and the industry, has recently extended its offering scope to vaccine related products, including but not limited to: vaccine excipients, nucleic acid delivery excipients, cell culture media and pharmaceutical packaging. “Always bearing in mind that what customers truly need is the top ...
-
Matexcel Provides Expansive Array of Bio-ink Products for Different Applications
Matexcel, a leading innovator in advanced materials and bioengineering, today announced its diverse portfolio of bio-ink products, empowering researchers across various fields to unlock the potential of 3D bioprinting. This comprehensive range, featuring tailored bio-inks for specific applications, paves the way for revolutionary advancements in regenerative medicine, drug discovery, and beyond. ...
By Matexcel
-
Alfa Chemistry Excels in mRNA Vaccine Development, Production, Optimization, and Quality Control
In the face of global health crises such as the COVID-19 pandemic, the development and production of vaccines have become paramount to safeguarding public health and restoring normalcy. Among the various vaccine technologies, mRNA vaccines have emerged as a groundbreaking solution, offering promising results in the fight against infectious diseases. Alfa Chemistry, a renowned scientific research ...
-
Exosome Targeting Services at Creative Biolabs Ready to Boost Drug Delivery Research
Exosomes are picking up steam among scientists because they can perform a role in the immune response, antigen presentation, cell migration, cell differentiation, and tumor invasion. Exosomes, which provide a mechanism for macromolecules to be exchanged between cells, play a part in the development of various illnesses, particularly in the modulation of the cancer microenvironment and immune ...
-
BioLingus to Develop a Sublingual Vaccine for COVID in Cooperation With the Korean CHA Vaccine Institute and PanGen Biotech
Biolingus IP II GmbH and the CHA Vaccine Institute Co., Ltd., with support from the Korean biotech company PanGen Biotech Inc., will collaborate to develop a sublingual vaccine for COVID. The project has received research funding from The Research Investment for Global Health Technology Fund (The RIGHT Fund). The RIGHT Fund is a Public-Private Partnership (PPP) funding agency between the ...
By BioLingus AG
-
Enesi Pharma Achieves Key Milestone in Development of Thermostable Solid-dose Live Vaccines against Measles and Rubella
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained activity against Measles and Rubella. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you